Drug Topics

SEPTEMBER 4, 2024

DaylightRX from Big Health is a digital formulation of cognitive behavioral therapy and is available by prescription only.

FDA 209

FDA 209

Pharmacy Times

SEPTEMBER 4, 2024

In a promising development in multiple sclerosis research, tolebrutinib delayed the onset of disability progression in patients with nrSPMS.

148

148

Drug Topics

SEPTEMBER 4, 2024

Embecta’s new patch pump offers a larger insulin reservoir to better accommodate for the needs of patients with type 2 diabetes (T2D).

FDA 200

FDA 200

STAT

SEPTEMBER 4, 2024

With fall coming into view, public health officials across the country are turning to the annual task of persuading legions of Americans to get vaccinated against some combination of influenza, Covid-19, and respiratory syncytial virus, three bugs that sicken mass numbers of people over the winter months, often overwhelming hospitals and health care delivery in the process.

Vaccines 145

Vaccines Hospitals 145

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

SEPTEMBER 4, 2024

Kristen Hartzell, PharmD, Vice President of Clinical Services, RedSail Technologies, sat down with Drug Topics to discuss the RxCash+ tool designed to achieve fairer pricing on cash prescriptions for pharmacies and patients.

184

184

STAT

SEPTEMBER 4, 2024

The emergence of a second mpox outbreak in which the virus is spreading from person-to-person, as well as a sharp increase in overall cases of the disease in several African countries, is straining the world’s capacity to make and distribute vaccine to battle the threat. New options are needed, and a study published Wednesday suggests another may be on the horizon.

Vaccines 143

Vaccines 143

STAT

SEPTEMBER 4, 2024

There it was on James Cannon’s lab report, two tiny words: African American. The words sat next to a number estimating how badly Cannon’s kidneys were failing. And they were definitely failing. His number read 37, less than half of what is considered normal for adults. Oddly, he thought, a different number labeled “if not African American” read even lower: 31.

Labelling 139

Labelling 139

Pharmacy Times

SEPTEMBER 4, 2024

New insights into heart failure risks in Native American communities are highlighting the need to address social determinants of health.

131

131

STAT

SEPTEMBER 4, 2024

Roughly 10% of people enrolled in Humana’s private Medicare plans will have to find new coverage for next year as the company trims its offerings in what’s become a turbulent corner of the industry.  Humana, the country’s second largest Medicare Advantage insurer, is aggressively culling its plan offerings after several quarters of spending more than expected on its members’ medical care, and getting hammered on Wall Street for it.

Insurance 130

Insurance 130

Pharmacy Times

SEPTEMBER 4, 2024

The findings demonstrate a need for additional health care provider training and resources for birthing people with intellectual and developmental disabilities.

130

130

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

SEPTEMBER 4, 2024

When you have a baby, sleep becomes the holy grail. You become convinced that getting your baby to go the hell to sleep depends on the right swaddles, the right pacifier, the right settings on the white noise machine, the right order of events. If a routine gets disrupted or a special object misplaced, you fear that the kid will be awake for days, and thus, so will you.

130

130

Fierce Healthcare

SEPTEMBER 4, 2024

Humana reaffirmed its full-year guidance but is leaving 13 Medicare Advantage (MA) markets next year, Chief Financial Officer Susan Diamond said during the Wells Fargo Healthcare Conference on Wedn | Humana is pulling back from Medicare Advantage markets and cutting benefits next year. The insurer expects it will lose thousands of members and supplemental benefit utilization will be high toward the end of this year.

Insurance 126

Insurance 126

STAT

SEPTEMBER 4, 2024

Novartis is opening a new manufacturing facility in California and expanding an existing production site in its bid to dominate the booming radiopharmaceuticals field amid burgeoning competition. The pharmaceutical giant will spend more than $200 million to construct the new facility in Carlsbad, Calif., and expand its site in Indianapolis, representatives told STAT exclusively.

124

124

Pharmacy Times

SEPTEMBER 4, 2024

Alirocumab (Praluent; Regeneron), is a PCSK9 inhibitor indicated for the treatment of adults with heterozygous familiar hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease.

123

123

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Fierce Healthcare

SEPTEMBER 4, 2024

Centene’s business is still impacted by Medicaid redeterminations, a process that began in early 2023, the company said during the Wells Fargo Healthcare Conference. | Centene's stock sunk Wednesday after the company highlighted issues it faces surrounding Medicaid redeterminations.

122

122

Pharmacy Times

SEPTEMBER 4, 2024

OBX-115 could offer further treatment options for individuals with advanced or metastatic melanoma by enhancing persistence, antitumor activity, and clinical safety of TIL cell therapy.

FDA 123

FDA 123

Fierce Pharma

SEPTEMBER 4, 2024

Over the last decade, three blockbuster drugs—Biogen’s Spinraza, Roche’s Evrysdi and Novartis’ gene therapy Zolgensma—have transformed the treatment landscape for spinal muscular atrophy (SMA). | Biogen revealed that a portion of its phase 2/3 DEVOTE study met its primary endpoint, as a higher dose of Spinraza improved the motor function of treatment-naive infants with spinal muscular atrophy.

119

119

Fierce Healthcare

SEPTEMBER 4, 2024

Over the past several years, Humana has made significant strides in growing its senior-focused primary care business, and a new study highlights areas where it's seeing success in this model. | Over the past several years, Humana has made significant strides in growing its senior-focused primary care business, and a new study highlights areas where it's seeing success in this model.

118

118

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Fierce Pharma

SEPTEMBER 4, 2024

Several months after its parent company unveiled new labs and office space to unite cell and gene therapy research on the West Coast, Astellas Gene Therapies is turning out the lights at a Californ | Several months after its parent company unveiled new labs and office space to unite cell and gene therapy research on the West Coast, Astellas Gene Therapies is turning out the lights at a California production plant.

119

119

STAT

SEPTEMBER 4, 2024

Depression has many faces. Some people can’t sleep, while others struggle to get out of bed. Even though symptoms and severity can vary from person to person, a recent study found that a specific brain circuit might be associated with the mental malady.  Located in the prefrontal cortex, the brain’s cognitive control circuit plays a part in our attention, goal-setting behavior and other executive functioning.

115

115

BioPharm

SEPTEMBER 4, 2024

As the field of bioanalytical testing evolves, it is important for drug developers to stay at the forefront of the advancements to ensure they remain competitive.

114

114

Drug Topics

SEPTEMBER 4, 2024

Dana Krug, Senior Vice President of Cold Chain Fulfillment at Phononic, explained the current state of his company’s cooling technology and the common trends of temperature control throughout the industry.

112

112

pharmaphorum

SEPTEMBER 4, 2024

Digital skills: Why private clinics need effective communication lines to bridge the growing digital divide Mike.

Communication 111

Communication 111

Drug Topics

SEPTEMBER 4, 2024

Click Therapeutics announced that CT-132 met its primary endpoint in the phase 3 ReMMi-D trial.

112

112

Fierce Healthcare

SEPTEMBER 4, 2024

Evernorth's Accredo specialty pharmacy will offer biosimilars for the popular immunotherapy Stelara at $0 for eligible patients, the company announced Thursday. | Evernorth's Accredo specialty pharmacy will offer biosimilars for the popular immunotherapy Stelara at $0 for eligible patients, the company announced Thursday.

Specialty Pharmacies 111

Specialty Pharmacies 111

STAT

SEPTEMBER 4, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning. If your local deserted mall were to be shut down, would you rather it be turned into a shiny new arena for your basketball team or a shiny new biomedical innovation hub? That’s apparently the dilemma the business community is facing in Philadelphia.

110

110

Fierce Healthcare

SEPTEMBER 4, 2024

Microplastics are everywhere, including our bodies. | In this week's episode of "Podnosis," two experts break down the history of plastics use in the healthcare sector and what it would take for an organization to phase them out.

111

111

Fierce Pharma

SEPTEMBER 4, 2024

With a shortage of ADHD drugs persisting, the DEA has raised production limits on Takeda’s Vyvanse and its generic versions by 24%, the agency said.

105

105

The Checkup by Singlecare

SEPTEMBER 4, 2024

Anyone who has ever woken up with a stuffy or runny nose has gone through the same thought process before getting up and reaching for a tissue: First, they hope it’s just the common cold or allergies. And second, they hope it’s not a sinus infection. Why? Unlike colds, which are caused by a virus and can be pesky but work themselves out in a day or two, sinus infections are bacterial and often stick around for ten days or more and come with symptoms like nasal congestion , postnasal drip , facia

Vaccines 105

Vaccines Insurance Immunization 105

pharmaphorum

SEPTEMBER 4, 2024

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).The full results of the FENopta open-label extension study are due to be reported in full at the ECTRIMS congress in Copenhagen later this month, but top-line findings include that 99% of patients treated with fenebrutinib were free of T1 gadolinium-enhancing lesions, markers of active inflammation, at 48 w

Labelling 105

Labelling 105

Pharmaceutical Technology

SEPTEMBER 4, 2024

Actimed says S-oxprenolol shares a similar pharmacology to its lead product S-pindolol, which is being studied in cachexia.

FDA 105

FDA 105

Pharmaceutical Commerce

SEPTEMBER 4, 2024

The latest news for pharma industry insiders.

104

104

PharmaVoice

SEPTEMBER 4, 2024

More companies are investing in protein degraders, which leverage a unique approach to harnessing the immune system in cancer, neurological diseases and more.

Immunization 104

Immunization 104